Syngene International Limited (SYNGENE.NS)
Runs labs that help drug companies discover and develop new medicines
414.25+0.01%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-41.1%
The outlook
SYNGENE.NS is trading near its 52-week lows with most analysts favoring a buy stance. The stock sits well below its key moving averages, suggesting weak recent momentum, though the average analyst price target implies meaningful upside from current levels. The elevated P/E ratio reflects higher valuation relative to earnings.
What’s behind the score
Analyst consensusBuy — 2.1 avg of 8 analysts
Price trendBelow its 50- & 200-day averages
52-week range10% of the way from its 52-week low to high
Price targetAvg target +35% vs current price
Analyst price target
~12-month · 8 analysts559.38average target+35.0% vs now
Now 414.25
Low 410.00High 735.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$166.74B
52-wk high
728.60
52-wk low
380.00
50-day avg
436.49
200-day avg
504.28
Trailing P/E
52.7